Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Allogene Therapeutics (ALLO) Stock Price & Analysis
1,073 Followers
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.23 - $6.89
Previous Close$3.07
Volume1.34M
Average Volume (3M)2.25M
Market Cap
$524.12M
Enterprise Value$163.77M
Total Cash (Recent Filing)$448.70M
Total Debt (Recent Filing)$88.35M
Price to Earnings (P/E)-1.5
Beta1.47
Next Earnings
Aug 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding169,091,992
10 Day Avg. Volume2,126,021
30 Day Avg. Volume2,249,499
Standard Deviation0.21
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.01
Price to Sales (P/S)5464.34
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.72K
Enterprise Value/Gross Profit1.72K
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$13.23Price Target Upside330.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Allogene Therapeutics News
PremiumCompany Announcements
Allogene Therapeutics’ Stability Threatened by Banking Sector TurmoilBulls Say, Bears Say
Bulls Say
Clinical Development ProgressThe ALPHA2 Phase1b trial for r/r CLL has begun enrolling, suggesting progress in Allogene's clinical developments.
Financial StabilityAllogene Therapeutics has a strong cash position of $448.7MM, indicating a robust financial status.
Innovation In TreatmentALLO-329 incorporates Dagger technology and targets both CD19 and CD70, positioning it as a potential differentiated player in autoimmune treatments.
Bears Say
Development TimelinesAnalyst maintains a Market Perform rating due to uncertainties regarding development timelines for Allogene Therapeutics.
Earnings4Q23 financial results fell short with an EPS of ($0.51) compared to the estimated ($0.42)
Financial PerformanceAllogene recorded a net loss of $0.51 per share—wider than the estimated net loss.
---
Ownership Overview
37.39% Insiders
29.76% Mutual Funds
14.99% Other Institutional Investors
17.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $2.23 and its highest was $6.89 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 93 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 170,723,100 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 17M.
---
Allogene Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.23 (330.94% Upside)
$13.23 (330.94% Upside)
Blogger Sentiment
Neutral
ALLO Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $682.1 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q4 2024
0:00 / 0:00
---
ALLO Stock 12 Months Forecast
Average Price Target
$13.23
▲(330.94% Upside)
Technical Analysis
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Editas Medicine
―
Beam Therapeutics
―
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-21.98%
reiterated a buy rating 2 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.98% per trade.
---